← Eichor
Condition: Thalassaemia Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Thalassaemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]
EARLY_Phase 1 · 1 location(s) · First Affiliated Hospital of Guangxi Medical University · NCT05762510Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy
Phase N/A · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT05991336ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia
Phase 1/Phase 2 · 1 location(s) · Children's Hospital of Philadelphia · NCT06364774A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel
Phase N/A · 6 location(s) · Genetix Biotherapeutics Inc. · NCT06271512Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
Phase 1 · 1 location(s) · Daniel Bauer · NCT06647979Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia
Phase 1/Phase 2 · 1 location(s) · The Hospital for Sick Children · NCT05426252Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling
EARLY_Phase 1 · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT06313398Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploid
Phase 2 · 5 location(s) · Rongrong Liu · NCT06657391Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
Phase 1 · 1 location(s) · Abdullah Kutlar · NCT01245179Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
Phase 1/Phase 2 · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT07599176Adherence of Beta Thalssemia Patients to Oral Chelation Therapy
NA · 1 location(s) · Sohag University · NCT06568926Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients
Phase 2 · 8 location(s) · Rongrong Liu · NCT07338344Safety and Efficacy of RM-004 Cells for Hemoglobin H-Constant Spring Disease
EARLY_Phase 1 · 1 location(s) · The 923rd Hospital of Joint Logistics Support Force of Peopl · NCT06107400Β-Thalassemia Treatment with KL003 Cell Injection
Phase 1/Phase 2 · 2 location(s) · Kanglin Biotechnology (Hangzhou) Co., Ltd. · NCT06280378the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia
EARLY_Phase 1 · 1 location(s) · Shenzhen Hemogen · NCT05864170A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Phase 3 · 105 location(s) · Novo Nordisk A/S · NCT06609226RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)
Phase N/A · 1 location(s) · Hospital Universitari Vall d'Hebron Research Institute · NCT06213402Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients
EARLY_Phase 1 · 1 location(s) · Shenzhen Hemogen · NCT05745532T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
Phase 1/Phase 2 · 1 location(s) · Paul Szabolcs · NCT03653338A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia
Phase 2 · 5 location(s) · Kind Pharmaceuticals LLC · NCT06302491A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an
Phase 2 · 6 location(s) · Memorial Sloan Kettering Cancer Center · NCT05736419A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or
Phase N/A · 2 location(s) · Bristol-Myers Squibb · NCT06073860Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Di
Phase 1 · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT05904093ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Phase N/A · 71 location(s) · American Thrombosis and Hemostasis Network · NCT04398628AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Phase 2 · 1 location(s) · Mitchell Cairo · NCT04099966Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Phase N/A · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT03937817European Rare Blood Disorders Platform (ENROL)
Phase N/A · 1 location(s) · Hospital Universitari Vall d'Hebron Research Institute · NCT06250595Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Phase 2 · 26 location(s) · Celgene · NCT04143724the Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia
EARLY_Phase 1 · 1 location(s) · Shenzhen Hemogen · NCT05851105Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise
Phase N/A · 2 location(s) · Medical College of Wisconsin · NCT03775954
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.